{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T03:37:39Z","timestamp":1791949059142,"version":"4.3.4"},"reference-count":125,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2024,8,31]],"date-time":"2024-08-31T00:00:00Z","timestamp":1725062400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"Zavante Therapeutics, Inc., Delaware, USA"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Treatment of patients with serious infections due to resistant Gram-negative bacteria remains highly problematic and has prompted clinicians to use existing antimicrobial agents in innovative ways. One approach gaining increased therapeutic use is combination therapy with IV fosfomycin. This article reviews the preclinical pharmacokinetic\/pharmacodynamic (PK\/PD) infection model and clinical data surrounding the use of combination therapy with IV fosfomycin for the treatment of serious infections caused by resistant Gram-negative bacteria. Data from dynamic in vitro and animal infection model studies of highly resistant Enterobacterales and non\u2013lactose fermenters are positive and suggest IV fosfomycin in combination with a \u03b2-lactam, polymyxin or aminoglycoside produces a synergistic effect that rivals or surpasses that of other aminoglycoside- or polymyxin-containing regimens. Clinical studies performed to date primarily have involved patients with pneumonia and\/or bacteraemia due to Klebsiella pneumoniae, Pseudomonas aeruginosa or Acinetobacter baumannii. Overall, the observed success rates with fosfomycin combination regimens were consistent with those reported for other combination regimens commonly used to treat these patients. In studies in which direct treatment comparisons can be derived, the results suggest that patients who received fosfomycin combination therapy had similar or improved outcomes compared with other therapies and combinations, especially when it was used in combination with a \u03b2-lactam that (1) targets PBP-3 and (2) has exceptional stability in the presence of \u03b2-lactamases. Collectively, the data indicate that combination therapy with IV fosfomycin should be considered as a potential alternative to aminoglycoside or polymyxin combinations for patients with antibiotic-resistant Gram-negative infections when benefits outweigh risks.<\/jats:p>","DOI":"10.1093\/jac\/dkae253","type":"journal-article","created":{"date-parts":[[2024,8,31]],"date-time":"2024-08-31T10:43:00Z","timestamp":1725100980000},"page":"2421-2459","source":"Crossref","is-referenced-by-count":20,"title":["Combination therapy with IV fosfomycin for adult patients with serious Gram-negative infections: a review of the literature"],"prefix":"10.1093","volume":"79","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0528-771X","authenticated-orcid":false,"given":"David A","family":"Butler","sequence":"first","affiliation":[{"name":"Department of Pharmacy Practice, Albany College of Pharmacy and Health Sciences , 106 New Scotland Avenue, Albany, NY 12208 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0921-549X","authenticated-orcid":false,"given":"Nimish","family":"Patel","sequence":"additional","affiliation":[{"name":"Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego , 9255 Pharmacy Lane, La Jolla, CA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5184-1385","authenticated-orcid":false,"given":"J Nicholas","family":"O\u2019Donnell","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, Albany College of Pharmacy and Health Sciences , 106 New Scotland Avenue, Albany, NY 12208 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4730-0655","authenticated-orcid":false,"given":"Thomas P","family":"Lodise","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, Albany College of Pharmacy and Health Sciences , 106 New Scotland Avenue, Albany, NY 12208 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,8,31]]},"reference":[{"key":"2024093023503954900_dkae253-B1","volume-title":"IDSA antimicrobial-resistant treatment guidance: Gram-Negative Bacterial Infections","author":"Tamma PD, Heil EL, Justo JA","year":"2024"},{"key":"2024093023503954900_dkae253-B2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciad428","volume-title":"Infectious Diseases Society of America guidance on the treatment of AmpC \u03b2-lactamase-producing Enterobacterales, carbapenem-resistant Acinetobacter baumannii, and Stenotrophomonas maltophilia infections","author":"Tamma","year":"2023,"},{"key":"2024093023503954900_dkae253-B3","doi-asserted-by":"publisher","first-page":"iii2","DOI":"10.1093\/jac\/dky027","article-title":"Treatment of infections caused by multidrug-resistant Gram-negative bacteria: report of the British Society for Antimicrobial Chemotherapy\/Healthcare Infection Society\/British Infection Association Joint Working Party\u2020","volume":"73","author":"Hawkey","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"2024093023503954900_dkae253-B4","doi-asserted-by":"publisher","first-page":"e13594","DOI":"10.1111\/ctr.13594","article-title":"Multidrug-resistant Gram-negative bacterial infections in solid organ transplant recipients\u2014guidelines from the American Society of Transplantation Infectious Diseases Community of Practice","volume":"33","author":"Pouch","year":"2019","journal-title":"Clin Transplant"},{"key":"2024093023503954900_dkae253-B5","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/j.cmi.2021.11.025","article-title":"European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European Society of Intensive Care Medicine)","volume":"28","author":"Paul","year":"2022","journal-title":"Clin Microbiol Infect"},{"key":"2024093023503954900_dkae253-B6","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1002\/phar.1868","article-title":"Past, present, and future of antibacterial economics: increasing bacterial resistance, limited antibiotic pipeline, and societal implications","volume":"37","author":"Luepke","year":"2016","journal-title":"Pharmacotherapy"},{"key":"2024093023503954900_dkae253-B7","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1093\/cid\/ciw593","article-title":"Economic incentives for antibacterial drug development: literature review and considerations from the transatlantic task force on antimicrobial resistance","volume":"63","author":"Sciarretta","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2024093023503954900_dkae253-B8","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.drup.2011.02.005","article-title":"Conserving antibiotics for the future: new ways to use old and new drugs from a pharmacokinetic and pharmacodynamic perspective","volume":"14","author":"Mouton","year":"2011","journal-title":"Drug Resist Updat"},{"key":"2024093023503954900_dkae253-B9","doi-asserted-by":"publisher","first-page":"e0446","DOI":"10.1097\/CCE.0000000000000446","article-title":"Setting the beta-lactam therapeutic range for critically ill patients: is there a floor or even a ceiling?","volume":"3","author":"Barreto","year":"2021","journal-title":"Crit Care Explor"},{"key":"2024093023503954900_dkae253-B10","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1128\/CMR.00101-15","article-title":"Inhaled antibiotics for Gram-negative respiratory infections","volume":"29","author":"Wenzler","year":"2016","journal-title":"Clin Microbiol Rev"},{"key":"2024093023503954900_dkae253-B11","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1002\/cpt.2198","article-title":"Model-informed drug development for anti-infectives: state of the art and future","volume":"109","author":"Rayner","year":"2021","journal-title":"Clin Pharmacol Ther"},{"key":"2024093023503954900_dkae253-B12","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/S1473-3099(20)30796-9","article-title":"Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial","volume":"21","author":"Bassetti","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"2024093023503954900_dkae253-B13","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1007\/s40121-018-0214-1","article-title":"Effect and safety of meropenem-vaborbactam versus best-available therapy in patients with carbapenem-resistant Enterobacteriaceae infections: the TANGO II randomized clinical trial","volume":"7","author":"Wunderink","year":"2018","journal-title":"Infect Dis Ther"},{"key":"2024093023503954900_dkae253-B14","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1093\/cid\/ciz530","article-title":"RESTORE-IMI 1: a multicenter, randomized, double-blind trial comparing efficacy and safety of imipenem\/relebactam vs colistin plus imipenem in patients with imipenem-nonsusceptible bacterial infections","volume":"70","author":"Motsch","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2024093023503954900_dkae253-B15","doi-asserted-by":"publisher","first-page":"2795","DOI":"10.1128\/AAC.05360-11","article-title":"Dosing regimen matters: the importance of early intervention and rapid attainment of the pharmacokinetic\/pharmacodynamic target","volume":"56","author":"Martinez","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"2024093023503954900_dkae253-B16","doi-asserted-by":"publisher","first-page":"33","DOI":"10.3390\/antibiotics11010033","article-title":"An evidence-based multidisciplinary approach focused on creating algorithms for targeted therapy of Infection-Related Ventilator-Associated Complications (IVACs) caused by Pseudomonas aeruginosa and Acinetobacter baumannii in critically ill adult patients","volume":"11","author":"Gatti","year":"2021","journal-title":"Antibiotics (Basel)"},{"key":"2024093023503954900_dkae253-B17","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1592\/phco.26.9.1320","article-title":"Application of antimicrobial pharmacodynamic concepts into clinical practice: focus on beta-lactam antibiotics: insights from the Society of Infectious Diseases Pharmacists","volume":"26","author":"Lodise","year":"2006","journal-title":"Pharmacotherapy"},{"key":"2024093023503954900_dkae253-B18","doi-asserted-by":"publisher","first-page":"2813","DOI":"10.1093\/jac\/dkx221","article-title":"Determination of alternative ceftolozane\/tazobactam dosing regimens for patients with infections due to Pseudomonas aeruginosa with MIC values between 4 and 32 mg\/L","volume":"72","author":"Natesan","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"2024093023503954900_dkae253-B19","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1164\/rccm.201505-0857OC","article-title":"A multicenter randomized trial of continuous versus intermittent \u03b2-lactam infusion in severe sepsis","volume":"192","author":"Dulhunty","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"key":"2024093023503954900_dkae253-B20","doi-asserted-by":"publisher","first-page":"e61","DOI":"10.1093\/cid\/ciw353","article-title":"Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society","volume":"63","author":"Kalil","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2024093023503954900_dkae253-B21","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1128\/CMR.00068-15","article-title":"Fosfomycin","volume":"29","author":"Falagas","year":"2016","journal-title":"Clin Microbiol Rev"},{"key":"2024093023503954900_dkae253-B22","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1111\/j.1749-6632.1974.tb43277.x","article-title":"The mechanism of action of fosfomycin (phosphonomycin)","volume":"235","author":"Kahan","year":"1974","journal-title":"Ann N Y Acad Sci"},{"key":"2024093023503954900_dkae253-B23","doi-asserted-by":"publisher","first-page":"e00464","DOI":"10.1128\/AAC.00464-18","article-title":"Phase I study to evaluate the pharmacokinetics, safety, and tolerability of two dosing regimens of oral fosfomycin tromethamine in healthy adult participants","volume":"62","author":"Wenzler","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2024093023503954900_dkae253-B24","unstructured":"European Committee on Antimicrobial Susceptibility Testing\n          . Breakpoint tables for interpretation of MICs and zone diameters. Version 13.1, 2023. http:\/\/www.eucast.org"},{"key":"2024093023503954900_dkae253-B25","article-title":"IVOZFO (fosfomycin sodium for injection) [package insert]","author":"Verity Pharmaceuticals","year":"2019"},{"key":"2024093023503954900_dkae253-B26"},{"key":"2024093023503954900_dkae253-B27","volume-title":"Critically important antimicrobials for human medicine, 6th revision","author":"World Health Organization","year":"2019"},{"key":"2024093023503954900_dkae253-B28","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/S1473-3099(09)70325-1","article-title":"Fosfomycin for the treatment of multidrug-resistant, including extended-spectrum beta-lactamase producing, Enterobacteriaceae infections: a systematic review","volume":"10","author":"Falagas","year":"2010","journal-title":"Lancet Infect Dis"},{"key":"2024093023503954900_dkae253-B29","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/s00228-010-0794-5","article-title":"Synergy of fosfomycin with other antibiotics for Gram-positive and Gram-negative bacteria","volume":"66","author":"Kastoris","year":"2010","journal-title":"Eur J Clin Pharmacol"},{"key":"2024093023503954900_dkae253-B30","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.mimet.2015.09.014","article-title":"A meta-analysis of in vitro antibiotic synergy against Acinetobacter baumannii","volume":"119","author":"March","year":"2015","journal-title":"J Microbiol Methods"},{"key":"2024093023503954900_dkae253-B31","doi-asserted-by":"publisher","first-page":"500","DOI":"10.3390\/antibiotics9080500","article-title":"Fosfomycin as partner drug for systemic infection management. A systematic review of its synergistic properties from in vitro and in vivo studies","volume":"9","author":"Antonello","year":"2020","journal-title":"Antibiotics (Basel)"},{"key":"2024093023503954900_dkae253-B32","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1016\/j.ijantimicag.2019.02.016","article-title":"Multidrug-resistant Acinetobacter baumannii infections: current evidence on treatment options and role of PK\/PD in dose optimization","volume":"53","author":"Lim","year":"2019","journal-title":"Int J Antimicrob Agents"},{"key":"2024093023503954900_dkae253-B33","doi-asserted-by":"publisher","first-page":"1914","DOI":"10.1128\/AAC.40.8.1914","article-title":"Comparison of three different in vitro methods of detecting synergy: time-kill, checkerboard, and E test","volume":"40","author":"White","year":"1996","journal-title":"Antimicrob Agents Chemother"},{"key":"2024093023503954900_dkae253-B34","doi-asserted-by":"publisher","first-page":"4678","DOI":"10.1128\/AAC.00497-10","article-title":"Synergy testing by Etest, microdilution checkerboard, and time-kill methods for pan-drug-resistant Acinetobacter baumannii","volume":"54","author":"Sopirala","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"2024093023503954900_dkae253-B35","doi-asserted-by":"publisher","first-page":"3708","DOI":"10.1128\/AAC.02779-13","article-title":"Amikacin-fosfomycin at a five-to-two ratio: characterization of mutation rates in microbial strains causing ventilator-associated pneumonia and interactions with commonly used antibiotics","volume":"58","author":"Montgomery","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"2024093023503954900_dkae253-B36","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1128\/CMR.05041-11","article-title":"Combination therapy for treatment of infections with gram-negative bacteria","volume":"25","author":"Tamma","year":"2012","journal-title":"Clin Microbiol Rev"},{"key":"2024093023503954900_dkae253-B37","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/S0002-9343(89)80611-4","article-title":"Antibiotic therapy for Pseudomonas aeruginosa bacteremia: outcome correlations in a prospective study of 200 patients","volume":"87","author":"Hilf","year":"1989","journal-title":"Am J Med"},{"key":"2024093023503954900_dkae253-B38","doi-asserted-by":"publisher","first-page":"O267","DOI":"10.1111\/1469-0691.12374","article-title":"Cell-wall-inhibiting antibiotic combinations with activity against multidrug-resistant Klebsiella pneumoniae and Escherichia coli","volume":"20","author":"Hickman","year":"2014","journal-title":"Clin Microbiol Infect"},{"key":"2024093023503954900_dkae253-B39","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1016\/j.ijantimicag.2015.07.019","article-title":"The combination of colistin and fosfomycin is synergistic against NDM-1-producing Enterobacteriaceae in in vitro pharmacokinetic\/pharmacodynamic model experiments","volume":"46","author":"Albur","year":"2015","journal-title":"Int J Antimicrob Agents"},{"key":"2024093023503954900_dkae253-B40","doi-asserted-by":"publisher","first-page":"246","DOI":"10.3389\/fcimb.2017.00246","article-title":"In vitro pharmacokinetics\/pharmacodynamics evaluation of fosfomycin combined with amikacin or colistin against KPC2-producing Klebsiella pneumoniae","volume":"7","author":"Yu","year":"2017","journal-title":"Front Cell Infect Microbiol"},{"key":"2024093023503954900_dkae253-B41","doi-asserted-by":"publisher","first-page":"577","DOI":"10.2147\/IDR.S160474","article-title":"In vitro antibacterial effect of fosfomycin combination therapy against colistin-resistant Klebsiella pneumoniae","volume":"11","author":"Yu","year":"2018","journal-title":"Infect Drug Resist"},{"key":"2024093023503954900_dkae253-B42","doi-asserted-by":"publisher","first-page":"5720417","DOI":"10.1155\/2018\/5720417","article-title":"Synergistic activity of colistin\/fosfomycin combination against carbapenemase-producing Klebsiella pneumoniae in an in vitro pharmacokinetic\/pharmacodynamic model","volume":"2018","author":"Wang","year":"2018","journal-title":"Biomed Res Int"},{"key":"2024093023503954900_dkae253-B43","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1016\/S0924-8579(03)00047-5","article-title":"Target site bacterial killing of cefpirome and fosfomycin in critically ill patients","volume":"21","author":"Zeitlinger","year":"2003","journal-title":"Int J Antimicrob Agents"},{"key":"2024093023503954900_dkae253-B44","doi-asserted-by":"publisher","first-page":"5602","DOI":"10.1128\/AAC.00752-15","article-title":"Pharmacodynamics of fosfomycin: insights into clinical use for antimicrobial resistance","volume":"59","author":"Docobo-Perez","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2024093023503954900_dkae253-B45","doi-asserted-by":"publisher","first-page":"1985","DOI":"10.1093\/jac\/dkx070","article-title":"Pharmacodynamics of colistin and fosfomycin: a \u2018treasure trove\u2019 combination combats KPC-producing Klebsiella pneumoniae","volume":"72","author":"Zhao","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"2024093023503954900_dkae253-B46","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.ijantimicag.2018.02.010","article-title":"Polymyxin B and fosfomycin thwart KPC-producing Klebsiella pneumoniae in the hollow-fibre infection model","volume":"52","author":"Bulman","year":"2018","journal-title":"Int J Antimicrob Agents"},{"key":"2024093023503954900_dkae253-B47","doi-asserted-by":"publisher","first-page":"e01815","DOI":"10.1128\/AAC.01815-17","article-title":"Evaluation of activity and emergence of resistance of polymyxin B and ZTI-01 (fosfomycin for injection) against KPC-producing Klebsiella pneumoniae","volume":"62","author":"Diep","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2024093023503954900_dkae253-B48","doi-asserted-by":"publisher","first-page":"105861","DOI":"10.1016\/j.ijantimicag.2019.105861","article-title":"Effect of drug combinations on the kinetics of antibiotic resistance emergence in Escherichia coli CFT073 using an in vitro hollow-fibre infection model","volume":"55","author":"Garimella","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"2024093023503954900_dkae253-B49","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1002\/cpt.2197","article-title":"Evaluation strategies for triple-drug combinations against carbapenemase-producing Klebsiella pneumoniae in an in vitro hollow-fiber infection model","volume":"109","author":"Garcia","year":"2021","journal-title":"Clin Pharmacol Ther"},{"key":"2024093023503954900_dkae253-B50","doi-asserted-by":"publisher","first-page":"e0029321","DOI":"10.1128\/AAC.00293-21","article-title":"Amikacin combined with fosfomycin for treatment of neonatal sepsis in the setting of highly prevalent antimicrobial resistance","volume":"65","author":"Darlow","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"2024093023503954900_dkae253-B51","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1093\/jac\/dkac038","article-title":"Flomoxef and fosfomycin in combination for the treatment of neonatal sepsis in the setting of highly prevalent antimicrobial resistance","volume":"77","author":"Darlow","year":"2022","journal-title":"J Antimicrob Chemother"},{"key":"2024093023503954900_dkae253-B52","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.3390\/antibiotics11121705","article-title":"Evaluation of a sequential antibiotic treatment regimen of ampicillin, ciprofloxacin and fosfomycin against Escherichia coli CFT073 in the hollow fiber infection model compared with simultaneous combination treatment","volume":"11","author":"Krishna","year":"2022","journal-title":"Antibiotics (Basel)"},{"key":"2024093023503954900_dkae253-B53","doi-asserted-by":"publisher","first-page":"e02213","DOI":"10.1128\/AAC.02213-20","article-title":"Activity of fosfomycin and amikacin against fosfomycin-heteroresistant Escherichia coli strains in a hollow-fiber infection model","volume":"65","author":"Portillo-Calder\u00f3n","year":"2023","journal-title":"Antimicrob Agents Chemother"},{"key":"2024093023503954900_dkae253-B54","doi-asserted-by":"publisher","first-page":"e0331823","DOI":"10.1128\/spectrum.03318-23","article-title":"Pharmacokinetic\/pharmacodynamic analysis of ceftazidime\/avibactam and fosfomycin combinations in an in vitro hollow fiber infection model against multidrug-resistant Escherichia coli","volume":"12","author":"Kroemer","year":"2024","journal-title":"Microbiol Spectr"},{"key":"2024093023503954900_dkae253-B55","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1038\/s41467-017-01929-y","article-title":"A general pharmacodynamic interaction model identifies perpetrators and victims in drug interactions","volume":"8","author":"Wicha","year":"2017","journal-title":"Nat Commun"},{"key":"2024093023503954900_dkae253-B56","doi-asserted-by":"publisher","first-page":"e01763","DOI":"10.1128\/AAC.01763-16","article-title":"Pharmacodynamics of aerosolized fosfomycin and amikacin against resistant clinical isolates of Pseudomonas aeruginosa and Klebsiella pneumoniae in a hollow-fiber infection model: experimental basis for combination therapy","volume":"61","author":"Sime","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2024093023503954900_dkae253-B57","doi-asserted-by":"publisher","first-page":"e01682","DOI":"10.1128\/AAC.01682-18","article-title":"The combination of fosfomycin plus meropenem is synergistic for Pseudomonas aeruginosa PAO1 in a hollow-fiber infection model","volume":"62","author":"Drusano","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2024093023503954900_dkae253-B58","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.3390\/antibiotics11111578","article-title":"Evaluation of fosfomycin-sulbactam combination therapy against carbapenem-resistant Acinetobacter baumannii isolates in a hollow-fibre infection model","volume":"11","author":"Mohd Sazlly Lim","year":"2022","journal-title":"Antibiotics (Basel)"},{"key":"2024093023503954900_dkae253-B59","doi-asserted-by":"publisher","first-page":"e01375","DOI":"10.1128\/AAC.01375-20","article-title":"Clinical pharmacokinetics of fosfomycin after continuous infusion compared with intermittent infusion: a randomized crossover study in healthy volunteers","volume":"65","author":"Al Jalali","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"2024093023503954900_dkae253-B60","doi-asserted-by":"publisher","first-page":"7094","DOI":"10.1128\/AAC.01032-15","article-title":"Optimizing the initial amikacin dosage in adults","volume":"59","author":"White","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2024093023503954900_dkae253-B61","doi-asserted-by":"publisher","first-page":"999","DOI":"10.3389\/fmicb.2015.00999","article-title":"Assessment of combination therapy in BALB\/c mice injected with carbapenem-resistant Enterobacteriaceae strains","volume":"6","author":"Salloum","year":"2015","journal-title":"Front Microbiol"},{"key":"2024093023503954900_dkae253-B62","doi-asserted-by":"publisher","first-page":"3074","DOI":"10.1093\/jac\/dky283","article-title":"Activity of fosfomycin alone or combined with temocillin in vitro and in a murine model of peritonitis due to KPC-3- or OXA-48-producing Escherichia coli","volume":"73","author":"Berleur","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"2024093023503954900_dkae253-B63","doi-asserted-by":"publisher","first-page":"615540","DOI":"10.3389\/fmed.2021.615540","article-title":"Efficacy of fosfomycin and its combination with aminoglycosides in an experimental sepsis model by carbapenemase-producing Klebsiella pneumoniae clinical strains","volume":"8","author":"Cebrero-Cangueiro","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"2024093023503954900_dkae253-B64","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1093\/jac\/dkab378","article-title":"Activity of the combination of colistin and fosfomycin against NDM-1-producing Escherichia coli with variable levels of susceptibility to colistin and fosfomycin in a murine model of peritonitis","volume":"77","author":"Le Menestrel","year":"2021","journal-title":"J Antimicrob Chemother"},{"key":"2024093023503954900_dkae253-B65","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1016\/j.ijantimicag.2013.12.001","article-title":"Activity of fosfomycin alone or combined with cefoxitin in vitro and in vivo in a murine model of urinary tract infection due to Escherichia coli harbouring CTX-M-15-type extended-spectrum beta-lactamase","volume":"43","author":"Lefort","year":"2014","journal-title":"Int J Antimicrob Agents"},{"key":"2024093023503954900_dkae253-B66","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1128\/AAC.01718-12","article-title":"Activities of fosfomycin, tigecycline, colistin, and gentamicin against extended-spectrum-\u03b2-lactamase-producing Escherichia coli in a foreign-body infection model","volume":"57","author":"Corvec","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"2024093023503954900_dkae253-B67","doi-asserted-by":"publisher","first-page":"2666","DOI":"10.1093\/jac\/dkz257","article-title":"Efficacy of colistin alone and in various combinations for the treatment of experimental osteomyelitis due to carbapenemase-producing Klebsiella pneumoniae","volume":"74","author":"Cr\u00e9mieux","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"2024093023503954900_dkae253-B68","doi-asserted-by":"publisher","first-page":"106702","DOI":"10.1016\/j.ijantimicag.2022.106702","article-title":"Efficacy of ceftazidime-avibactam in various combinations for the treatment of experimental osteomyelitis due to Klebsiella pneumoniae carbapenemase (KPC)-producing Klebsiella pneumoniae","volume":"61","author":"Davido","year":"2023","journal-title":"Int J Antimicrob Agents"},{"key":"2024093023503954900_dkae253-B69","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1093\/jac\/dkad070","article-title":"Efficacy of ceftazidime\/avibactam in various combinations for the treatment of experimental osteomyelitis in rabbits caused by OXA-48-\/ESBL-producing Escherichia coli","volume":"78","author":"Davido","year":"2023","journal-title":"J Antimicrob Chemother"},{"key":"2024093023503954900_dkae253-B70","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1093\/jac\/4.6.569","article-title":"Interaction of fosfomycin with other antimicrobial agents: in vitro and in vivo studies","volume":"4","author":"Olay","year":"1978","journal-title":"J Antimicrob Chemother"},{"key":"2024093023503954900_dkae253-B71","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1093\/jac\/dkp224","article-title":"Synergistic effects of aminoglycosides and fosfomycin on Pseudomonas aeruginosa in vitro and biofilm infections in a rat model","volume":"64","author":"Cai","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"2024093023503954900_dkae253-B72","doi-asserted-by":"publisher","first-page":"e0157757","DOI":"10.1371\/journal.pone.0157757","article-title":"Activity of colistin in combination with meropenem, tigecycline, fosfomycin, fusidic acid, rifampin or sulbactam against extensively drug-resistant Acinetobacter baumannii in a murine thigh-infection model","volume":"11","author":"Fan","year":"2016","journal-title":"PLoS One"},{"key":"2024093023503954900_dkae253-B73","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1093\/infdis\/jiz149","article-title":"Ceftazidime-avibactam in combination with fosfomycin: a novel therapeutic strategy against multidrug-resistant Pseudomonas aeruginosa","volume":"220","author":"Papp-Wallace","year":"2019","journal-title":"J Infect Dis"},{"key":"2024093023503954900_dkae253-B74","doi-asserted-by":"publisher","first-page":"17127","DOI":"10.1038\/s41598-019-53714-0","article-title":"In vivo efficacy of combination of colistin with fosfomycin or minocycline in a mouse model of multidrug-resistant Acinetobacter baumannii pneumonia","volume":"9","author":"Ku","year":"2019","journal-title":"Sci Rep"},{"key":"2024093023503954900_dkae253-B75","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1128\/AAC.39.2.496","article-title":"Comparative efficacies of ciprofloxacin and pefloxacin alone or in combination with fosfomycin in experimental endocarditis induced by multidrug-susceptible and -resistant Pseudomonas aeruginosa","volume":"39","author":"Xiong","year":"1995","journal-title":"Antimicrob Agents Chemother"},{"key":"2024093023503954900_dkae253-B76","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1007\/BF02447919","article-title":"Bactericidal effect of pefloxacin and fosfomycin against Pseudomonas aeruginosa in a rabbit endocarditis model with pharmacokinetics of pefloxacin in humans simulated in vivo","volume":"16","author":"Bugnon","year":"1997","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2024093023503954900_dkae253-B77","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1007\/BF01644272","article-title":"Fosfomycin-ampicillin versus gentamicin-ampicillin in the treatment of critically ill patients with pneumonia","volume":"14","author":"Nissen","year":"1986","journal-title":"Infection"},{"key":"2024093023503954900_dkae253-B78","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1086\/657249","article-title":"Use of high-dose 4-hour infusion of doripenem, in combination with fosfomycin, for treatment of carbapenem-resistant Pseudomonas aeruginosa pneumonia","volume":"51","author":"Apisarnthanarak","year":"2010","journal-title":"Clin Infect Dis"},{"key":"2024093023503954900_dkae253-B79","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.ijantimicag.2011.11.012","article-title":"Carbapenem-resistant Pseudomonas aeruginosa pneumonia with intermediate minimum inhibitory concentrations to doripenem: combination therapy with high-dose, 4\u2013h infusion of doripenem plus fosfomycin versus intravenous colistin plus fosfomycin","volume":"39","author":"Apisarnthanarak","year":"2012","journal-title":"Int J Antimicrob Agents"},{"key":"2024093023503954900_dkae253-B80","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/s40121-020-00357-8","article-title":"Efficacy of a fosfomycin-containing regimen for treatment of severe pneumonia caused by multidrug-resistant Acinetobacter baumannii: a prospective, observational study","volume":"10","author":"Russo","year":"2021","journal-title":"Infect Dis Ther"},{"key":"2024093023503954900_dkae253-B81","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.3390\/antibiotics11081007","article-title":"Ceftazidime\/avibactam in ventilator-associated pneumonia due to difficult-to-treat non-fermenter gram-negative bacteria in COVID-19 patients: a case series and review of the literature","volume":"11","author":"Burastero","year":"2022","journal-title":"Antibiotics (Basel)"},{"key":"2024093023503954900_dkae253-B82","doi-asserted-by":"publisher","first-page":"106825","DOI":"10.1016\/j.ijantimicag.2023.106825","article-title":"Efficacy of cefiderocol- vs colistin-containing regimen for treatment of bacteraemic ventilator-associated pneumonia caused by carbapenem-resistant Acinetobacter baumannii in patients with COVID-19","volume":"62","author":"Russo","year":"2023","journal-title":"Int J Antimicrob Agents"},{"key":"2024093023503954900_dkae253-B83","doi-asserted-by":"publisher","first-page":"E72","DOI":"10.1111\/1469-0691.12091","article-title":"Bacteraemia due to OXA-48-carbapenemase-producing Enterobacteriaceae: a major clinical challenge","volume":"19","author":"Navarro-San Francisco","year":"2013","journal-title":"Clin Microbiol Infect"},{"key":"2024093023503954900_dkae253-B84","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.1016\/j.jiph.2021.09.025","article-title":"Efficacy and safety of intravenous fosfomycin for the treatment of difficult-to-treat Gram-negative bacterial infections","volume":"14","author":"Abdallah","year":"2021","journal-title":"J Infect Public Health"},{"key":"2024093023503954900_dkae253-B85","doi-asserted-by":"publisher","first-page":"dlac121","DOI":"10.1093\/jacamr\/dlac121","article-title":"Effect of ceftazidime\/avibactam plus fosfomycin combination on 30 day mortality in patients with bloodstream infections caused by KPC-producing Klebsiella pneumoniae: results from a multicentre retrospective study","volume":"4","author":"Oliva","year":"2022","journal-title":"JAC-Antimicrobal Resistance"},{"key":"2024093023503954900_dkae253-B86","doi-asserted-by":"publisher","first-page":"286","DOI":"10.3390\/pathogens12020286","article-title":"Efficacy of fosfomycin-containing regimens for treatment of bacteremia due to pan-drug resistant Acinetobacter baumannii in critically ill patients: a case series study","volume":"12","author":"Assimakopoulos","year":"2023","journal-title":"Pathogens"},{"issue":"Suppl 1","key":"2024093023503954900_dkae253-B87","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1159\/000222083","article-title":"Evaluation of fosfomycin in an intensive care unit","volume":"23","author":"Pardo Zubiris","year":"1977","journal-title":"Chemotherapy"},{"key":"2024093023503954900_dkae253-B88","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1179\/joc.2005.17.5.527","article-title":"Second-line treatment of limb-threatening diabetic foot infections with intravenous fosfomycin","volume":"17","author":"Stengel","year":"2005","journal-title":"J Chemother"},{"key":"2024093023503954900_dkae253-B89","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1111\/j.1469-0691.2009.02921.x","article-title":"Intravenous fosfomycin for the treatment of nosocomial infections caused by carbapenem-resistant Klebsiella pneumoniae in critically ill patients: a prospective evaluation","volume":"16","author":"Michalopoulos","year":"2010","journal-title":"Clin Microbiol Infect"},{"key":"2024093023503954900_dkae253-B90","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.ijantimicag.2010.09.002","article-title":"Adverse events associated with intravenous fosfomycin","volume":"37","author":"Florent","year":"2011","journal-title":"Int J Antimicrob Agents"},{"key":"2024093023503954900_dkae253-B91","doi-asserted-by":"publisher","first-page":"182","DOI":"10.3109\/00365548.2011.616221","article-title":"Fosfomycin: efficacy against infections caused by multidrug-resistant bacteria","volume":"44","author":"Dinh","year":"2012","journal-title":"Scand J Infect Dis"},{"key":"2024093023503954900_dkae253-B92","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.ijantimicag.2013.09.010","article-title":"Outcomes of critically ill intensive care unit patients treated with fosfomycin for infections due to pandrug-resistant and extensively drug-resistant carbapenemase-producing Gram-negative bacteria","volume":"43","author":"Pontikis","year":"2014","journal-title":"Int J Antimicrob Agents"},{"key":"2024093023503954900_dkae253-B93","doi-asserted-by":"publisher","first-page":"5598","DOI":"10.1128\/AAC.02435-13","article-title":"Preliminary study of colistin versus colistin plus fosfomycin for treatment of carbapenem-resistant Acinetobacter baumannii infections","volume":"58","author":"Sirijatuphat","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"2024093023503954900_dkae253-B94","doi-asserted-by":"publisher","first-page":"317","DOI":"10.4103\/ijccm.IJCCM_454_16","article-title":"A study of 24 patients with colistin-resistant Gram-negative isolates in a tertiary care hospital in South India","volume":"21","author":"Arjun","year":"2017","journal-title":"Indian J Crit Care Med"},{"key":"2024093023503954900_dkae253-B95","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1093\/jac\/dky406","article-title":"Fosfomycin in severe infections due to genetically distinct pan-drug-resistant Gram-negative microorganisms: synergy with meropenem","volume":"74","author":"Perdig\u00e3o Neto","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"2024093023503954900_dkae253-B96","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1007\/s15010-019-01323-4","article-title":"Current clinical use of intravenous fosfomycin in ICU patients in two European countries","volume":"47","author":"Putensen","year":"2019","journal-title":"Infection"},{"key":"2024093023503954900_dkae253-B97","doi-asserted-by":"publisher","first-page":"516","DOI":"10.3947\/ic.2020.52.4.516","article-title":"Fosfomycin dosing regimens based on monte carlo simulation for treated carbapenem-resistant Enterobacteriaceae infection","volume":"52","author":"Kanchanasurakit","year":"2020","journal-title":"Infect Chemother"},{"key":"2024093023503954900_dkae253-B98","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.3855\/jidc.14125","article-title":"Retrospective evaluation of intravenous fosfomycin in multi-drug resistant infections at a tertiary care hospital in Lebanon","volume":"15","author":"Ballouz","year":"2021","journal-title":"J Infect Dev Ctries"},{"key":"2024093023503954900_dkae253-B99","doi-asserted-by":"publisher","first-page":"652","DOI":"10.3390\/antibiotics10060652","article-title":"Cefiderocol-based combination therapy for \u201cdifficult-to-treat\u201d Gram-negative severe infections: real-life case series and future perspectives","volume":"10","author":"Bavaro","year":"2021","journal-title":"Antibiotics (Basel)"},{"key":"2024093023503954900_dkae253-B100","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1007\/s40121-021-00479-7","article-title":"Ceftazidime-avibactam in combination with in vitro non-susceptible antimicrobials versus ceftazidime-avibactam in monotherapy in critically ill patients with carbapenem-resistant Klebsiella pneumoniae infection: a retrospective cohort study","volume":"10","author":"Zheng","year":"2021","journal-title":"Infect Dis Ther"},{"key":"2024093023503954900_dkae253-B101","doi-asserted-by":"publisher","first-page":"e0214221","DOI":"10.1128\/aac.02142-21","article-title":"Cefiderocol- compared to colistin-based regimens for the treatment of severe infections caused by carbapenem-resistant Acinetobacter baumannii","volume":"66","author":"Falcone","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"2024093023503954900_dkae253-B102","doi-asserted-by":"publisher","first-page":"699","DOI":"10.3947\/ic.2022.0098","article-title":"Prescription pattern of intravenous fosfomycin in a provincial hospital in Thailand","volume":"54","author":"Thampithak","year":"2022","journal-title":"Infect Chemother"},{"key":"2024093023503954900_dkae253-B103","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.3390\/antibiotics11121739","article-title":"Pharmacokinetic\/pharmacodynamic analysis of continuous-infusion fosfomycin in combination with extended-infusion cefiderocol or continuous-infusion ceftazidime-avibactam in a case series of difficult-to-treat resistant Pseudomonas aeruginosa bloodstream infections and\/or hospital-acquired pneumonia","volume":"11","author":"Gatti","year":"2022","journal-title":"Antibiotics (Basel)"},{"key":"2024093023503954900_dkae253-B104","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1080\/1120009X.2022.2149186","article-title":"Efficacy and safety of intravenous fosfomycin for the treatment of carbapenem-resistant Klebsiella pneumoniae","volume":"35","author":"Aysert-Yildiz","year":"2023","journal-title":"J Chemother"},{"key":"2024093023503954900_dkae253-B105","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.jgar.2023.03.012","article-title":"Ceftazidime\/avibactam-resistant meropenem-susceptible KPC-producing Klebsiella pneumoniae: analysis of cases and evaluation of in vitro activity of fosfomycin-containing combinations","volume":"33","author":"Oliva","year":"2023","journal-title":"J Glob Antimicrob Resist"},{"key":"2024093023503954900_dkae253-B106","doi-asserted-by":"publisher","first-page":"971","DOI":"10.3390\/antibiotics12060971","article-title":"The use of intravenous fosfomycin in clinical practice: a 5-year retrospective study in a tertiary hospital in Italy","volume":"12","author":"Anastasia","year":"2023","journal-title":"Antibiotics (Basel)"},{"key":"2024093023503954900_dkae253-B107","doi-asserted-by":"publisher","first-page":"984","DOI":"10.3390\/microorganisms11040984","article-title":"Cefiderocol-based versus colistin-based regimens for severe carbapenem-resistant Acinetobacter baumannii infections: a propensity score-weighted, retrospective cohort study during the first two years of the COVID-19 pandemic","volume":"11","author":"Mazzitelli","year":"2023","journal-title":"Microorganisms"},{"key":"2024093023503954900_dkae253-B108","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.jgar.2023.03.010","article-title":"Real-life experience with IV fosfomycin in Canada: results from the Canadian LEadership on Antimicrobial Real-life usage (CLEAR) registry","volume":"33","author":"Zhanel","year":"2023","journal-title":"J Glob Antimicrob Resist"},{"key":"2024093023503954900_dkae253-B109","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1002\/phar.2209","article-title":"International consensus guidelines for the optimal use of the polymyxins: endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti-infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP)","volume":"39","author":"Tsuji","year":"2019","journal-title":"Pharmacotherapy"},{"key":"2024093023503954900_dkae253-B110","article-title":"Fosfomycin intravenous: rationale for EUCAST clinical breakpoints","author":"EUCAST"},{"key":"2024093023503954900_dkae253-B111","author":"EUCAST"},{"key":"2024093023503954900_dkae253-B112","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.1093\/cid\/ciz181","article-title":"Fosfomycin for injection (ZTI-01) versus piperacillin-tazobactam for the treatment of complicated urinary tract infection including acute pyelonephritis: ZEUS, a phase 2\/3 randomized trial","volume":"69","author":"Kaye","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2024093023503954900_dkae253-B113","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1093\/jac\/dkae111","article-title":"Population pharmacokinetic\/pharmacodynamic target attainment analysis of IV fosfomycin for the treatment of MDR Gram-negative bacterial infections","volume":"79","author":"Wangchinda","year":"2024","journal-title":"J Antimicrob Chemother"},{"key":"2024093023503954900_dkae253-B114","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/S1473-3099(14)70850-3","article-title":"Framework for optimisation of the clinical use of colistin and polymyxin B: the prato polymyxin consensus","volume":"15","author":"Nation","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"2024093023503954900_dkae253-B115","doi-asserted-by":"publisher","first-page":"e2137277","DOI":"10.1001\/jamanetworkopen.2021.37277","article-title":"Effectiveness of fosfomycin for the treatment of multidrug-resistant Escherichia coli bacteremic urinary tract infections: a randomized clinical trial","volume":"5","author":"Sojo-Dorado","year":"2022","journal-title":"JAMA Network Open"},{"key":"2024093023503954900_dkae253-B116","volume-title":"WHO global report on sodium intake reduction","author":"World Health Organization","year":"2023"},{"key":"2024093023503954900_dkae253-B117","doi-asserted-by":"publisher","first-page":"2825","DOI":"10.1093\/jac\/dkz226","article-title":"Inoculum effect of \u03b2-lactam antibiotics","volume":"74","author":"Lenhard","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"2024093023503954900_dkae253-B118","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.cmi.2016.12.022","article-title":"Role of inoculum and mutant frequency on fosfomycin MIC discrepancies by agar dilution and broth microdilution methods in Enterobacteriaceae","volume":"23","author":"Ballestero-T\u00e9llez","year":"2017","journal-title":"Clin Microbiol Infect"},{"key":"2024093023503954900_dkae253-B119","doi-asserted-by":"publisher","first-page":"7170","DOI":"10.1128\/AAC.04955-14","article-title":"Exploration of the pharmacokinetic-pharmacodynamic relationships for fosfomycin efficacy using an in vitro infection model","volume":"59","author":"VanScoy","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2024093023503954900_dkae253-B120","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1186\/s12879-021-06253-x","article-title":"The role of combination therapy in the treatment of severe infections caused by carbapenem resistant gram-negatives: a systematic review of clinical studies","volume":"21","author":"Savoldi","year":"2021","journal-title":"BMC Infect Dis"},{"key":"2024093023503954900_dkae253-B121","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1186\/s13054-023-04457-y","article-title":"Association between combination antibiotic therapy as opposed as monotherapy and outcomes of ICU patients with Pseudomonas aeruginosa ventilator-associated pneumonia: an ancillary study of the iDIAPASON trial","volume":"27","author":"Foucrier","year":"2023","journal-title":"Crit Care"},{"key":"2024093023503954900_dkae253-B122","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/S1473-3099(18)30099-9","article-title":"Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial","volume":"18","author":"Paul","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"2024093023503954900_dkae253-B123","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2200131","article-title":"Colistin monotherapy versus combination therapy for carbapenem-resistant organisms","volume":"2","author":"Kaye","year":"2023","journal-title":"NEJM Evidence"},{"key":"2024093023503954900_dkae253-B124","doi-asserted-by":"publisher","first-page":"e02307-18","DOI":"10.1128\/AAC.02307-18","article-title":"Generating robust and informative nonclinical in vitro and in vivo bacterial infection model efficacy data to support translation to humans","volume":"63","author":"Bulitta","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2024093023503954900_dkae253-B125","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ccc.2010.11.003","article-title":"Pharmacokinetics and pharmacodynamics: optimal antimicrobial therapy in the intensive care unit","volume":"27","author":"Lodise","year":"2011","journal-title":"Crit Care Clin"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/79\/10\/2421\/59459962\/dkae253.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/79\/10\/2421\/59459962\/dkae253.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,30]],"date-time":"2024-09-30T23:50:55Z","timestamp":1727740255000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/79\/10\/2421\/7746492"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,31]]},"references-count":125,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2024,8,31]]},"published-print":{"date-parts":[[2024,10,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkae253","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,10]]},"published":{"date-parts":[[2024,8,31]]}}}